Community-Acquired Pneumonia Clinical Trial
Official title:
COMPARISON OF CLINICAL EFFICACY OF COMBINATION Amoxycillin Plus Clavulanic Acid and Oxacillin Plus Ceftriaxone for HOSPITAL TREATMENT OF COMMUNITY Acquired PNEUMONIA IN CHILDREN : A Randomized Clinical Study
Objective: To compare the clinical effectiveness and hospital costs, the initial empirical
treatment, Oxacillin / Ceftriaxone and Amoxicillin / Clavulanate in children with Community
Acquired Pneumonia (CAP) severe.
Methods: Clinical prospective randomized study in children aged two months to five years of
age with a diagnosis of severe CAP, according to criteria of World Health Organization
(WHO), admitted to the Pediatrics Ward of the Hospital of the Medical School of Botucatu-
UNESP. We excluded children with comorbid disorders (primary and secondary immunodeficiency)
with acute or chronic kidney disease, referred patients receiving antibiotics proposal and
history of allergy to antibiotics proposed. We included 104 children who were randomized
into two groups to receive: Oxacillin / Ceftriaxone IV (GCO, n = 48) and Amoxicillin /
Clavulanate IV (GAA, n = 56). Patients of the GAA, after clinical improvement, has been
receiving the same oral antibiotic, and maintaining clinical stability, were discharged from
hospital, the GOC received any IV treatment. The outcomes analyzed were time to clinical
improvement (fever and tachypnea), duration of oxygen therapy, hospitalization time, need to
expand the antimicrobial spectrum progression to pleural effusion / empyema (DP / E) and
hospital costs. Treatment failure was determined by the need to expand the antimicrobial
spectrum after 48 hours of hospitalization.
eligibility: Children aged two months to five years with diagnosis of severe community
acquired pneumonia, requiring hospitalization.
Outcomes measures: time to clinical improvement (respiratory rate and fever), duration of
oxygen therapy, length of stay in the Division of Pediatrics, evolution with clinical
complications, need for broadening the spectrum antimicrobials.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05722938 -
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
|
Phase 3 | |
| Terminated |
NCT04972318 -
Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia
|
N/A | |
| Recruiting |
NCT06065618 -
Characteristics of Hospitalized Patients With Community-acquired Pneumonia
|
||
| Not yet recruiting |
NCT03675178 -
Clinical Study of Anerning Particle for the Treatment of Childhood Community-acquired Pneumonia
|
Phase 4 | |
| Not yet recruiting |
NCT04166110 -
Antibiotic Therapy In Respiratory Tract Infections
|
N/A | |
| Completed |
NCT02380352 -
Short-course Antimicrobial Therapy for Paediatric Respiratory Infections
|
Phase 4 | |
| Completed |
NCT01671280 -
Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)
|
N/A | |
| Completed |
NCT02555852 -
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
|
N/A | |
| Recruiting |
NCT00752947 -
Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors
|
Phase 4 | |
| Completed |
NCT00140023 -
Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia
|
Phase 3 | |
| Recruiting |
NCT04089787 -
Shortened Antibiotic Treatment of 5 Days in Community-Acquired Pneumonia
|
Phase 4 | |
| Completed |
NCT05356494 -
Postural Drainage and PEP Technique in Community Acquired Pneumonia
|
N/A | |
| Completed |
NCT05133752 -
Oral Nemonoxacin in Treating Elderly Patients With CAP
|
Phase 4 | |
| Not yet recruiting |
NCT06291012 -
Stopping Pneumonia Antibiotherapy Regimen Early
|
Phase 4 | |
| Recruiting |
NCT05002192 -
A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia
|
||
| Completed |
NCT03452826 -
Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia
|
N/A | |
| Terminated |
NCT04071041 -
Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.
|
Phase 3 | |
| Completed |
NCT03474991 -
KIDS-STEP_Betamethasone Therapy in Hospitalised Children With CAP
|
Phase 3 | |
| Completed |
NCT01683487 -
Delayed Antibiotic Treatment in Community-acquired Pneumococcal Pneumonia.
|
Phase 4 | |
| Completed |
NCT01723644 -
Clinical Reassessment Versus Procalcitonin in Order to Shorten Antibiotic Duration in Community-acquired Pneumonia
|
N/A |